Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $1,151,558.10 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 120,582 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were acquired at an average price of $9.55 per share, for a total transaction of $1,151,558.10. Following the acquisition, the director directly owned 17,098,479 shares of the company’s stock, valued at approximately $163,290,474.45. The trade was a 0.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $6.91 per share, for a total transaction of $3,310,159.49.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV traded up $0.23 during mid-day trading on Tuesday, hitting $10.55. The company’s stock had a trading volume of 167,162 shares, compared to its average volume of 388,493. The firm has a market capitalization of $260.79 million, a P/E ratio of -2.99 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $14.53. The stock’s fifty day simple moving average is $8.83 and its two-hundred day simple moving average is $7.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics in the first quarter valued at about $131,000. OMERS ADMINISTRATION Corp acquired a new stake in Artiva Biotherapeutics during the fourth quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in Artiva Biotherapeutics during the first quarter valued at approximately $139,000.

Analysts Set New Price Targets

Several research firms recently commented on ARTV. Wedbush boosted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.